Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Hoth Therapeutics Inc (HOTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: HOTH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.31% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.82M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 828033 | Beta 0.85 | 52 Weeks Range 0.58 - 2.79 | Updated Date 04/1/2025 |
52 Weeks Range 0.58 - 2.79 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date 2025-03-26 | When After Market | Estimate -0.43 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.16% | Return on Equity (TTM) -83.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -878037 | Price to Sales(TTM) - |
Enterprise Value -878037 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 13147700 | Shares Floating 6838218 |
Shares Outstanding 13147700 | Shares Floating 6838218 | ||
Percent Insiders 0.92 | Percent Institutions 3.53 |
Analyst Ratings
Rating 5 | Target Price 4.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hoth Therapeutics Inc
Company Overview
History and Background
Hoth Therapeutics Inc. is a biopharmaceutical company focused on developing new therapies for unmet medical needs. Founded in 2017, the company aims to improve the lives of patients suffering from dermatological disorders and other conditions.
Core Business Areas
- Dermatology: Developing therapies for dermatological disorders such as atopic dermatitis (eczema).
- Novel Drug Delivery: Exploring novel drug delivery systems to improve therapeutic efficacy and patient compliance.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, regulatory affairs, and business management. The company operates with a structure typical of a small, research-focused biotech.
Top Products and Market Share
Key Offerings
- HT-001 (Atopic Dermatitis): A novel therapeutic for atopic dermatitis, currently in preclinical development. Market share is not yet applicable as the product is not yet on the market. Competitors include Sanofi/Regeneron (Dupixent) and Incyte (Opzelura).
- HT-ALZ (Alzheimer's Disease): A therapeutic for Alzheimer's Disease, currently in preclinical development. Market share is not yet applicable as the product is not yet on the market. Competitors include Eisai/Biogen (Leqembi) and Eli Lilly (Donanemab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with companies constantly striving to develop new and innovative therapies. The dermatology market is growing due to the increasing prevalence of skin disorders. Alzheimer's Disease market is growing due to the increasing prevalence of age-related dementias.
Positioning
Hoth Therapeutics is positioned as a small, innovative biotech company focused on developing novel therapies for dermatological disorders and other unmet medical needs. Its competitive advantage lies in its proprietary technologies and development pipeline.
Total Addressable Market (TAM)
The total addressable market for atopic dermatitis is estimated at billions of dollars globally. The total addressable market for Alzheimer's Disease is also estimated at billions of dollars globally. Hoth Therapeutics is positioned to capture a share of these markets with successful product development.
Upturn SWOT Analysis
Strengths
- Novel drug development pipeline
- Focus on unmet medical needs
- Experienced management team
- Proprietary technologies
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small company size
- Preclinical stage pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Government funding and grants
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- SNY
- LLY
- INCY
- BIIB
Competitive Landscape
Hoth Therapeutics faces significant competition from larger, more established pharmaceutical companies. The company's success depends on its ability to develop differentiated products and secure strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily focused on preclinical development and research activities.
Future Projections: Future growth is dependent on successful clinical trials and eventual commercialization of its products.
Recent Initiatives: Recent initiatives include advancing its lead compounds through preclinical studies and exploring potential partnerships.
Summary
Hoth Therapeutics is a preclinical-stage biopharmaceutical company with a focus on dermatology and other unmet medical needs. It has a promising pipeline, but faces risks associated with clinical trials and funding. Its success relies on successful product development and securing partnerships. The current lack of revenue and high cash burn rate mean that any positive movement in the pipeline would likely have a large impact on the share price.
Similar Companies
- ATXI
- CLNN
- LBRN
- CRBP
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hoth Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-02-15 | Founder, President, CEO & Chairman Mr. Robb Knie | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://hoththerapeutics.com |
Full time employees 2 | Website https://hoththerapeutics.com | ||
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.